We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 3.35
High: 3.35
Low: 3.35
Prev. Close: 3.35
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence

Mon, 20th Dec 2021 15:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

FireAngel Safety Technology Group PLC - Coventry, England-based fire safety firm - Confirms it remains on target to meet market expectations for adjusted loss before tax for 2021, representing a "significant improvement" on 2020. However, it expects revenue to be at the lower end of market expectations. Additionally, debt at year end is expected to be ahead of earlier forecasts. Highlights supply chain issues have continued to intensify during the second half of 2021, with rising costs and component shortages affecting the group's ability to build products and increase stock inventory to meet growing demand. FireAngel Executive Chair John Conoley comments: "The board is pleased that despite severe headwinds, the company is on track to deliver an improved financial performance in 2021 and to have sufficient working capital for its forecasted needs."

----------

ValiRx PLC - Nuneaton, England-based drug development company - Amends license deal with Cancer Research Technology to enable a range of sub-licensing options. The updated VAL201 license restates the terms of the agreement, including the payment schedule and terms for milestones, the expected development plan and provides additional flexibility to a sub-licensee. Additionally, under the new terms CRT is required to formally approve any sub-license which ValiRx enters into relating to VAL201. CRT has also now approved the terms of the sub-license between pharmaceutical consultant TheoremRx and ValiRx and consented for the transaction to proceed in due course. ValiRx Chief Executive Suzy Dilly comments: "This amendment updates the VAL201 license terms in a manner that aligns the license with of the proposed terms of the sub-license between ValiRx and TheoremRx."

----------

InnovaDerma PLC - London-based developer of beauty, personal care and life science products - Posts narrowed operating pretax loss and expects a return to profitability in financial 2022. For the financial year that ended June 30, revenue is GBP10.2 million, down 23% from GBP13.2 million the year before, and operating loss narrows to GBP1.9 million from GBP5.0 million. Highlights a change in strategy, shifting focus away from revenue generation at the expense of profits to an "e-commerce led business to generate sustainable profitable growth". "The board is optimistic that the transformation plan enacted this year, as well as underlying improved consumer consumption versus last year, will enable the business to return to profitability this year. The group has been trading in line with expectations, with retail momentum steadily returning in the UK beauty category to pre-pandemic levels," Innovaderma says.

----------

Capital Metals PLC - London-based mineral sands explorer - Suffers a USD1.2 million pretax loss for the first half ended September 30, widened from a USD354,000 loss a year before. The company is not yet revenue generating. States it is focused on securing first industrial mining license at the Eastern Minerals Project in Sri Lanka, expects to receive this in the first quarter of 2022. Chair Greg Martyr comments: "This has been a transformational period for Capital Metals culminating in the award of our environmental impact assessment permit on 22 November 2021, despite the significant difficulties experienced in Sri Lanka during the Covid-19 pandemic. The obtaining of the EIA demonstrates the Sri Lankan authorities' support for the project and should enable us to meet our target of commencing commercial production in less than 12 months' time."

----------

Sportech PLC - London-based betting technology company - Extends period of exclusivity for discussions on the sale of its terrestrial lottery supply contract until December 1. Emphasises that there is no certainty that the sale will proceed.

----------

Voyager Life PLC - Perth, Scotland-based hemp seed oil products supplier - Buys CBD skincare firms Cannafull and Ascend Skincare for a total of GBP9,000. The parent company of Cannafull and Ascend Skincare, Cannafull Ltd, has recently gone into liquidation and consequently Voyager's acquisition of the two brands has been made from the liquidator. The GBP9,000 price tag will be for the brands, their websites and social media platforms, all fixtures and fittings and remaining inventory. Voyager is not however buying the parent company or taking on any liabilities as part of the deal. Cannafull manufactures CBD skincare products while Ascend Skincare supplies three CBD-based face serums.

----------

Directa Plus PLC - graphene nanoplatelets supplier - Granted EU patent for company's G+ pristine graphene nanoplatelets, aimed at boosting the performance of rubber-based shoe outsoles. Following the grant of the patent, Directa Plus's intellectual property portfolio will comprise 18 patent families with 72 patents granted and 25 patents pending. Chief Executive and Founder Giulio Cesareo says: "This EU patent will reinforce our position in the fast-growing market for technical footwear, attracting the attention of the major consumer product players."

----------

WANdisco PLC - Sheffield-based data-management software company - Secures a USD3.3 million three-year license contract with an unnamed "large North American multinational investment bank" for the use of LiveData Migrator. WANdisco's revenue share will be 50% of the license under its long-standing original equipment manufacturer agreement with IBM. Following the contract win, management now expects financial year 2021 revenue to be "meaningfully ahead" of current market estimates.

----------

Marlowe PLC - London-based safety and regulatory compliance services and software - Buys e-learning provider Skill Boosters for an initial payment of GBP5.5 million with a growth-based contingent consideration expected to be around GBP2.5 million. Skill Boosters is described as an equality, diversity and inclusion e-learning course provider. Marlowe notes Skill Boosters will offer "attractive cross-sell and technology synergies with Marlowe's compliance software activities, of which eLearning forms a key part".

----------

Kistos PLC - investor in low-carbon energy assets, including in Dutch North Sea - Confirms interest in buying some of TotalEnergies SE's West Shetland gas assets. Following press speculation, Kistos says the potential purchase is in keeping with its stated strategy of growth through acquisition and that it would be funded using the company's existing cash reserves.

----------

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
21 Mar 2024 11:22

ValiRx inks evaluation deal with Imperial College London for research

(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeutic candidates for cancer treatment.

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Feb 2024 14:45

ValiRx says requisition notice from shareholder group is invalid

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice.

Read more
12 Feb 2024 12:59

ValiRx inks deal with Dundee Drug Discovery Unit

(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

Read more
12 Feb 2024 11:42

IN BRIEF: ValiRx signs research sharing deal with Dundee University

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics.

Read more
9 Feb 2024 20:24

TRADING UPDATES: ValiRx receives shareholder request for board change

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Dec 2023 15:56

UK shareholder meetings calendar - next 7 days

Friday 29 December 
Apollon Formularies PLCAGM
Eco Atlantic Oil & Gas LtdAGM
Genedrive PLCAGM
Goldplat PLCAGM
Lansdowne Oil & Gas PLCGM re capital raise
Marula Mining PLCAGM
Microsaic Systems PLCGM re fundraise
Online Blockchain PLCAGM
Secure Property Development & Investment PLCAGM
SkinBioTherapeutics PLCAGM
Tetragon Financial Group LtdAGM
Woodbois LtdAGM
Zambeef Products PLCAGM
Monday 1 January 
no events scheduled 
Tuesday 2 January 
no events scheduled 
Wednesday 3 January 
Jubilee Metals Group PLCGM re equity raise
Thursday 4 January 
Rotala PLCGM re management buyout
Tintra PLCGM re cancellation, re-registering as private company
ValiRx PLCGM re operational review
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
19 Dec 2023 20:46

IN BRIEF: ValiRx raises GBP192,200, part of wider GBP1.8 million raise

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Says 3.2 million new shares have been subscribed for at 6 pence per share via a retail offer, raising GBP192,244. Also issues 499,998 new shares via a subscription. In total, raises GBP1.8 million via placing, subscription and retail offer of 30.0 million new shares.

Read more
13 Dec 2023 21:14

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Dec 2023 15:08

ValiRx enters option deal with Ambrose Healthcare

(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.

Read more
5 Dec 2023 11:17

ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose

(Alliance News) - ValiRx PLC on Tuesday said that ValiSeek Ltd it has entered a deal to licence VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.

Read more
5 Dec 2023 10:59

AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
10 Nov 2023 11:49

ValiRx signs deal to evaluate StingRay Bio drug candidates

(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates.

Read more
10 Nov 2023 10:32

ValiRx enters partnership with StingRay Bio

(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.

Read more
6 Oct 2023 11:35

ValiRx sees no reason for shares jump; notes TheoremRx mulls merger

(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.